United StatesNew research suggests that reducing the dosage of certain cancer drugs, such as Keytruda, could save up to $30 billion globally each year while improving patient access. Studies presented at the American Society of Clinical Oncology’s annual conference indicated that lower doses may be equally effective. Merck & Co., the manufacturer of Keytruda, maintains that the FDA-approved dosages are supported by extensive clinical evidence.
Bias read (Center): The article presents findings from medical research and includes perspectives from both researchers and pharmaceutical companies without overtly favoring one side. It does not take a clear stance on the issue but reports on differing viewpoints.
